Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher immunoglobulin dosing to slow lung disease progression in primary antibody deficiency
NL-OMON49108Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2021
- Countries
- 1
01
Overview
Randomised, open-label trial of polyvalent human immunoglobulin in Primary antibody deficiency (PAD) and common variable immunodeficiency (CVID) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Progression of lung disease. Planned start Jan 2021; status: withdrawn.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Primary antibody deficiency (PAD)common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on NL-OMON49108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49108.